The prospect of eff ectively treating cancer patients with immunotherapy is now becoming a clinical reality. This is a consequence of clinically relevant and successful results obtained by applying monoclonal antibodies against immune checkpoint inhibitor receptors and chimeric antigen receptor (CAR) T cell therapy to patients with otherwise lethal cancers. Despite this success, only a limited number of cancer types and a subset of cancer patients currently respond to these therapies. Eff orts are now made to increase the number of cancer types and patients that can be treated successfully. This is an overview of the various approaches taken to this end.

Klinička imunoterapija onkoloških bolesnika je postala klinička realnost. To je posljedica klinički relevantnih i uspješnih rezultata dobivenih primjenom monoklonskih protutijela protiv imunoloških kontrolnih molekula funkcije inhibitornih receptora te T-limfocita s kimeričnim antigenskim receptorima. Usprkos tim uspješnim i obećavajućim rezultatima, rezultati su postignuti samo protiv dijela tumora i opet u samo dijela bolesnika se postiže terapijski odgovor. U prikazanom radu dan je kratak pregled tih raznih imunoterapijskih pristupa.